CY2027 MA Bids Lock In as Actuaries Navigate Tighter Margins

From modeling MA bid scenarios across multiple plan types over the past four bid cycles, a recurring pattern is clear: plans that optimize for Star Ratings bonus qualification consistently outperform on margin, and the CY2027 rules amplify that advantage. The June 1, 2026 bid deadline closed what may have been the most consequential MA pricing cycle since the V28 risk adjustment model reached full weight in CY2026. Plan actuaries locked in revenue projections, benefit designs, and premium structures against a regulatory environment that simultaneously improved baseline funding, deferred a major model recalibration, codified Part D redesign mechanics, and restructured the quality bonus system.

The headline number from the April 6 final rate announcement was favorable: a 2.48% net average payment increase, translating to approximately $13 billion in additional MA plan payments relative to CY2026. With estimated risk score trend from population aging and coding practices, the effective increase reaches 4.98%. But the headline obscures a more complex picture. Offsetting pressures from the unlinked chart review exclusion (a $7 billion negative for CRR-dependent plans), V28 compression residuals, and Part D cost overruns compress the usable margin for bid construction. Wakely estimates that under simplifying assumptions, risk-adjusted bid revenue is down roughly 0.35%, underscoring the sensitivity that dominated actuarial bid models heading into the June deadline.

The Rate Environment: Parsing 2.48% Into Bid-Level Revenue

The April rate announcement represented a 239 basis point positive swing from the January advance notice, which had projected just 0.09%. As we documented in our analysis of the rate reversal, three components drove nearly all of the swing: CMS's decision to retain the existing V28 risk adjustment model calibration (contributing roughly 220 basis points), the softened chart review exclusion via a new switching exception (adding 25 basis points), and updated Part A/B per-capita spending data (adding 36 basis points).

For bid actuaries, translating the aggregate 2.48% into plan-level revenue required decomposing the change by county, plan type, and population mix. The effective growth rate of 5.33% varies substantially across geographic markets. Counties with above-average FFS cost growth, particularly those experiencing strong inpatient utilization from the 2025/2026 respiratory season and elevated Part B drug spending in oncology and metabolic therapies, received proportionally larger benchmark increases. Plans concentrated in rural markets where FFS spending growth has lagged faced effective growth rates below the national average by 100 to 200 basis points.

For a plan with 100,000 members and a $1,200 monthly benchmark, the swing from the advance notice baseline added approximately $34 million in annual revenue relative to January projections. Plans that had begun preliminary bid construction against the 0.09% assumption faced meaningful rework in the eight weeks between rate announcement and bid deadline. The central strategic question for every plan actuary became where to allocate that incremental revenue: margin restoration, benefit enrichment, premium reduction, or provider rate increases.

V28 Model Deferral: Short-Term Relief, Medium-Term Cliff

The single most consequential regulatory decision for CY2027 bid construction was CMS's choice to defer the V28 risk adjustment model recalibration. Had CMS finalized its proposed update to the model's underlying calibration data, replacing the current 2018/2019 base with 2023/2024 data, Georgetown's analysis estimated the recalibration would have reduced aggregate payments by approximately 3.32%. Instead, plans continue operating under the existing V28 model at full weight, using calibration data that predates the COVID-19 pandemic, the GLP-1 revolution, and several structural shifts in Medicare spending patterns.

The deferral is a relief valve, not a permanent fix. V28 reached its full 100% weighting in CY2026, completing the multi-year transition from the prior V24 model. CMS cited a desire to allow the market more time to adjust following the completion of that phase-in. But from a bid construction perspective, the deferral creates an asymmetric risk profile. Plans benefit today from calibration data that systematically overpredicts costs for populations with certain condition mixes relative to what a recalibrated model would show. When CMS eventually finalizes the recalibration, likely in the CY2028 or CY2029 cycle, the accumulated divergence between 2018/2019 calibration data and current spending patterns means the adjustment will be larger than it would have been had it occurred in CY2027.

Prudent bid actuaries building three-year strategic projections incorporated a recalibration scenario with an estimated negative impact in the range of 3.5% to 4.5%, reflecting an additional year of data divergence beyond the 3.32% Georgetown estimated for CY2027. Plans that used the full CY2027 rate windfall for benefit enrichment without reserving for the recalibration cliff risk finding themselves in a worse position than plans that held margin in reserve. The deferral, in effect, separates plans with multi-year planning horizons from those optimizing for a single bid cycle.

Star Ratings Overhaul: $18.6 Billion Reshapes Bonus Math

The CY2027 final rule restructured Star Ratings in ways that alter the bid arithmetic for every plan at or near the 4.0-star threshold. CMS removed 11 administrative measures and added Depression Screening, shifting roughly 65% of total scoring weight to clinical outcomes and patient experience. The overall policy change sends an estimated $18.6 billion to MA insurers over the next decade through expanded bonus eligibility and lower quality penalty exposure.

The narrowing to clinical measures has a specific implication for bid construction. Plans that historically scored well on administrative metrics (call center hold times, complaint resolution speed, enrollment processing accuracy) may lose rating points, while plans with strong clinical performance and HEDIS measure compliance stand to gain. The net effect is a redistribution of plans across the star rating distribution, with Axene Health Partners estimating that the proportion of plans qualifying for quality bonus payments could increase by 8 to 12 percentage points. For plans on the margin between 3.5 and 4.0 stars, that shift can be worth 5% of revenue, a figure that dwarfs the base rate increase in its impact on the bid mathematics.

The Depression Screening measure introduces a new investment requirement. Plans must implement PHQ-2/PHQ-9 screening protocols, with an expected 10% to 15% positive screen rate requiring 30-day follow-up under the measure specification. The incremental PMPM cost ranges from $0.80 to $2.50 depending on network adequacy for behavioral health providers and existing screening infrastructure. Plans that had already invested in behavioral health integration gain a structural advantage; plans that deferred those investments face a compressed implementation timeline against the 2027 measurement year.

From tracking bid dynamics across prior cycles, the Star Ratings bonus is the single highest-leverage variable in bid construction. A plan at 4.0 stars receives a 5% benchmark bonus; a plan at 3.5 stars receives nothing. The 65% clinical weight rebalancing creates winners and losers that are largely determined before the bid spreadsheet opens, because clinical infrastructure investments take 18 to 24 months to produce measurable HEDIS improvements. Plans that recognized this trajectory early and invested in care management, quality analytics, and provider incentive programs during CY2025 and CY2026 entered the CY2027 bid cycle with a structural advantage their competitors cannot replicate on the bid timeline.

Part D Redesign Codification: Year-Two Pricing Under the IRA

CY2027 bids represent the second full year of Part D operations under the Inflation Reduction Act's restructured benefit design. The $2,000 annual out-of-pocket cap, modified catastrophic phase cost-sharing, and manufacturer discount obligations are now codified in the CY2027 final rule rather than operating under transitional authority. For MA-PD plan actuaries, codification provides pricing certainty that the first-year bid cycle lacked, but first-year claims experience introduced its own complications.

As we analyzed in our coverage of Part D year-one data, catastrophic phase utilization ran roughly 22% above the Milliman and Wakely base cases that plans used for CY2026 bid construction. The variance was concentrated in GLP-1 receptor agonists, oncology biologics, and autoimmune therapies where the reduced cost-sharing structure improved adherence and shifted utilization earlier in the benefit year. Plans that assumed conservative catastrophic phase utilization in CY2026 absorbed the miss through risk corridor recoveries, but CY2027 bids had to incorporate the observed utilization trajectory without that safety net at the same scale.

CMS also finalized separate RxHCC model segments for MA-PD plans and standalone PDPs, reflecting documented differences in their enrollee populations and formulary structures. The segmented approach improves predictive accuracy for MA-PD plans but creates a new source of plan-level variance in Part D risk-adjusted revenue. Plans with heavy specialty drug utilization (oncology, autoimmune, hepatitis C) may see improved prediction at the member level. Plans with predominantly generic-heavy formularies may see smaller benefits from the segmentation.

The CMS GLP-1 Bridge program, launching in July 2026 with a $50 monthly copay outside the Part D benefit structure, adds another variable. Plans constructing integrated Part C and Part D bids had to estimate the Bridge program's take-up rate and its interaction with existing formulary coverage decisions. CMS projects costs of $1.74 billion per million users, but the take-up modeling is highly uncertain in the first year. Plans that included conservative Bridge-related cost adjustments may find themselves with margin upside if actual take-up falls below projections, or with inadequate pricing if utilization exceeds expectations.

Chart Review Exclusion: The Plan-Level Revenue Cliff

The exclusion of diagnoses from unlinked chart review records from CY2027 risk score calculations remains the largest single negative pressure on bid revenue. CMS estimated the aggregate impact at 1.53% of total payments after introducing the switching exception, down from the originally proposed 1.78%. But the plan-level distribution around that average is highly skewed.

Plans with mature encounter-based coding infrastructure, where the vast majority of diagnoses flow through routine clinical encounters, primary care visits, and specialist claims, may see revenue impacts below 0.5%. Plans that relied heavily on retrospective chart review programs and in-home health risk assessments face reductions of 3% or more. The $7 billion aggregate hit falls disproportionately on organizations that built their revenue models around supplemental diagnosis capture.

The strategic response was already visible in the months before the bid deadline. Plans accelerated investment in prospective coding programs, retraining providers to document all active conditions during routine visits rather than relying on retrospective review. Oliver Wyman's April 2026 analysis recommended that plans "conduct a thorough review of supplemental benefits and SSBCI offerings to ensure they deliver measurable value while meeting heightened documentation standards." That guidance reflects the dual challenge: plans must simultaneously replace CRR-sourced revenue through better encounter coding and comply with strengthened CMS program integrity requirements for supplemental benefit documentation.

For plans in transition between retrospective and prospective coding models, the bid construction challenge is particularly acute. The revenue reduction from the CRR exclusion is immediate and quantifiable. The revenue recovery from improved encounter-based coding accrues gradually over 12 to 18 months as providers adapt workflows and EHR templates. That timing mismatch means CY2027 bids for CRR-dependent plans had to absorb a near-term margin compression that prospective coding improvements cannot fully offset within the contract year.

Supplemental Benefits: The Margin Variable Beneficiaries Notice

Supplemental benefit richness is the most visible output of the bid construction process and the primary competitive lever in beneficiary acquisition. Dental, vision, hearing, over-the-counter allowances, transportation, meals, and fitness benefits are funded from the rebate, which is the difference between a plan's bid and its county benchmark multiplied by the quality bonus percentage. Higher benchmarks and quality bonuses mean larger rebates and richer supplemental benefits; tighter margins mean benefit erosion.

KFF's 2026 Medicare Advantage Spotlight documented a notable trend: average Part C premiums declined from $16.40 to $14.00, but supplemental benefits eroded across OTC allowances, meal programs, and transportation categories. Our analysis of the KFF data showed that the apparent premium decline masked a real reduction in total benefit value per member. Plans were pricing to competitive premium points while absorbing V28 compression and utilization trend increases through benefit trimming rather than premium increases.

The CY2027 bid environment presents a fork in this trajectory. The favorable rate increase provides room to restore some of the supplemental benefit reductions from CY2026. But plans face a credibility problem with restored benefits: beneficiaries who experienced benefit cuts in CY2026 may have already switched plans during the Annual Enrollment Period, and the enrollment lost to benefit erosion does not automatically return when benefits are restored. UnitedHealthcare, which deliberately traded 1.3 million MA members for margin recovery through benefit repricing and 190-county exits, faces this dynamic acutely. The CY2027 rate environment makes county re-entry and benefit enrichment financially feasible, but the competitive landscape has shifted while those markets were vacated.

CMS also strengthened program integrity requirements for Special Supplemental Benefits for the Chronically Ill (SSBCI) in the CY2027 final rule, including eligibility documentation standards and new safeguards around debit card-based benefit delivery. Plans expanding SSBCI offerings must balance competitive positioning against tighter compliance expectations, adding administrative cost to what had been a relatively low-friction benefit category.

Bid Mathematics: A Component Walk-Through

To illustrate the trade-offs, consider a simplified bid scenario for a broad-market HMO with 50,000 members in a county with a $1,100 monthly benchmark and a 5% quality bonus (4.0+ stars).

Component	CY2026 Bid	CY2027 Bid	Change
County benchmark (PMPM)	$1,100	$1,155	+5.0%
Quality bonus (5%)	$55	$58	+$3
Adjusted benchmark	$1,155	$1,213	+$58
Plan bid (Part C)	$1,020	$1,065	+4.4%
Rebate (75% of difference)	$101	$111	+$10
Available for supplemental benefits	$101	$111	+9.9%
CRR exclusion impact (est.)	n/a	−$8	New
Net supplemental benefit budget	$101	$103	+$2

The example illustrates why the headline rate increase does not translate directly into richer benefits. The plan's bid incorporates higher medical cost trend (driving the bid from $1,020 to $1,065), the CRR exclusion reduces effective revenue, and Part D cost adjustments consume additional margin. The net gain in supplemental benefit budget is modest: roughly $2 PMPM in this scenario, or about $1.2 million annually for a 50,000-member plan. That is enough to restore a modest OTC allowance or expand a dental benefit from preventive-only to comprehensive coverage, but not enough to fund a significant benefit enrichment.

Plans with below-4.0 star ratings face a starker picture. Without the quality bonus, the adjusted benchmark is lower, the rebate is smaller, and the available supplemental benefit budget may actually decline in CY2027 despite the favorable headline rate. The Star Ratings overhaul amplifies this bifurcation: plans newly qualifying for 4.0 stars under the revised methodology gain access to the bonus for the first time, while plans that lose star rating points from the administrative measure removal face a double hit of lower benchmark adjustments and reduced competitive positioning.

Carrier-Level Positioning: Who Bid From Strength

The major MA carriers entered the CY2027 bid cycle from markedly different competitive positions, and those starting points shape how each organization likely allocated the rate increase across margin recovery, benefit investment, and market expansion.

UnitedHealthcare enters CY2027 bids having restored profitability through aggressive portfolio management. The company shed 1.3 million MA members during CY2026, driving its medical care ratio from near 90% to 83.9%. That margin recovery provides a cushion for benefit restoration in CY2027, but the company must decide whether re-entering exited counties is worth the acquisition cost when competitors like Humana have absorbed displaced members and built network relationships in those markets.

Humana absorbed roughly 1.2 million members from UHC's CY2026 exits, growing its MA book at the expense of higher initial medical loss ratios as new members seasoned into Humana's provider networks. The CY2027 bid cycle required Humana to demonstrate that the acquired membership is priced sustainably at the plan level, a test that depends on how effectively the company integrated those members into existing network contracts and care management programs.

CVS/Aetna also reduced service areas during CY2026 and faces a similar re-entry calculus to UnitedHealthcare. The CY2027 rate environment makes expansion more attractive, but CVS's broader corporate challenges (retail pharmacy closures, PBM regulatory scrutiny) may constrain the capital available for MA market development.

Patterns we have tracked across prior bid cycles suggest that carriers with strong Star Ratings positioning, established prospective coding infrastructure, and diversified MA portfolios across geographic markets are best positioned to convert the CY2027 rate increase into sustainable competitive advantage. Carriers that remain CRR-dependent, concentrated in sub-4.0-star plans, or overexposed to markets with below-average FFS cost growth face a more constrained bid environment despite the favorable headline number.

Network Adequacy and Provider Contracting Pressures

The CY2027 final rule strengthened network adequacy standards, building on the requirements implemented for CY2026. Plans expanding into new service areas or restoring coverage in previously exited counties must meet updated time-and-distance standards, provider type requirements, and essential community provider thresholds. The cost of building compliant networks in new geographies partially offsets the revenue benefit of re-entry.

Provider contracting interacts directly with the rate environment. The 4.98% effective increase provides plans with additional room in provider rate negotiations, but the wave of 21 health systems exiting MA networks in 2026, including Mayo Clinic, Mount Sinai, and Providence, demonstrates that provider willingness to participate is not purely a function of reimbursement levels. Administrative burden from prior authorization requirements, claims processing delays, and risk adjustment documentation have become as significant as fee schedules in provider contracting decisions.

Plans shifting from retrospective chart review to prospective encounter-based coding need active provider cooperation. Persuading primary care physicians and specialists to document all active conditions during each visit requires workflow changes, EHR template modifications, and often financial incentives embedded in provider contracts. These coding quality bonuses are incremental to the medical loss ratio and were modeled explicitly in CY2027 bids by plans managing the CRR transition.

What the Locked-In Bids Signal for CY2027

CMS publishes aggregate bid data in the fall, and plan-level benefit packages during the Annual Enrollment Period in October. But several signals from the bid environment suggest what beneficiaries and competitors should expect.

First, benefit erosion likely stabilized rather than reversed for most plans. The net margin improvement after accounting for medical trend, CRR exclusion, and Part D cost adjustments is modest. Plans probably restored targeted supplemental benefits where enrollment data showed the highest sensitivity to benefit changes, rather than broadly enriching the package.

Second, market re-entry by carriers that exited counties in CY2025 and CY2026 is likely selective rather than comprehensive. The rate environment supports re-entry in counties with strong FFS cost growth trends and adequate provider networks. Counties with thin provider markets or below-average benchmark growth are unlikely to see returning carriers.

Third, Part D formulary design is tighter. The catastrophic phase utilization overrun from CY2026 means plans priced CY2027 Part D bids with higher utilization assumptions, which compresses the available margin for Part C supplemental benefits in integrated MA-PD offerings. Plans may have tightened formulary coverage for high-cost specialty drugs or implemented additional utilization management controls to contain Part D cost variance.

Fourth, the Star Ratings overhaul creates a redistribution of competitive advantage that plays out over the next two to three bid cycles. Plans that invested early in clinical quality infrastructure locked in their advantage in CY2027. Plans that deferred those investments will see the gap widen as clinical measures accumulate more weight in the scoring methodology.

Why This Matters for Plan Actuaries

The CY2027 bid cycle crystallizes a structural shift in MA plan pricing from a single-variable optimization (rate adequacy) to a multi-dimensional problem where risk model calibration uncertainty, quality bonus mechanics, Part D cost variance, and diagnosis sourcing rules interact with different signs and magnitudes at the plan level. The aggregate rate increase is favorable. The plan-level impact distribution is wide. And the deferred V28 recalibration introduces a time dimension that penalizes short-horizon bid optimization.

For consulting actuaries advising MA plans, the post-bid period is not a lull. Plans need scenario analysis of the V28 recalibration impact for CY2028, prospective coding conversion monitoring, Depression Screening measure implementation tracking, and Part D cost variance reconciliation against CY2027 bid assumptions. Each of these feeds directly into the CY2028 bid strategy that begins forming in the fall.

For the profession broadly, the CY2027 cycle reinforces that MA plan pricing has moved beyond traditional health actuarial techniques. The interaction between regulatory policy decisions (model deferrals, diagnosis sourcing rules), quality measurement systems (Star Ratings restructuring), and benefit design mechanics (Part D IRA codification) requires actuaries to integrate regulatory intelligence, clinical quality analytics, and multi-year strategic modeling into the bid construction process. The plans that submitted the strongest CY2027 bids were not necessarily those with the best medical cost trend, but those with the most integrated view across all of these dimensions.